Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats

J. Iwamoto, T. Takeda, T. Katsumata, T. Tanaka, S. Ichimura, Y. Toyama

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The purpose of the present study was to determine whether etidronate treatment could prevent bone loss caused by orchidectomy (ORX) and unilateral sciatic neurectomy (NX) in adult male rats. Seventy-four male Wistar rats, aged 10 months, were randomly divided into eight groups: baseline controls (n = 10); age-matched sham-operated controls (AMC; n = 9); ORX (n = 9); NX (n = 10); ORX + NX (n = 9); ORX + etidronate treatment (ORX + E; n = 7); NX + E (n = 10); and ORX + NX + E (n = 10). Etidronate treatment (10 mg/kg per day subcutaneously) was initiated 2 weeks after surgery and was continued for 2 weeks. Four weeks after surgery, bone mineral density (BMD) of the proximal and middle tibia (PT and MT, respectively), distal and middle femur (DF and MF, respectively), and fourth lumbar vertebral body (LVB) was measured by dual-energy X-ray absorptiometry (Model DCS-600, Aloka, Tokyo, Japan). The mechanical properties of the MF and third LVB were measured by three-point bending and compression tests, respectively. Levels of urinary deoxypyridinoline (Dpd) and serum osteocalcin (Oc) were also measured by enzyme-linked immunosorbent assay. Four weeks of aging had no significant effects on BMD, bone mechanical properties, or bone markers. ORX significantly increased the levels of urinary Dpd and serum Oc, which resulted in significant decreases in BMD of the PT, MT, DF, MF, and fourth LVB, as well as the mechanical strength (maximum load) of the MF and third LVB. NX significantly increased levels of urinary Dpd and decreased levels of serum Oc, resulting in a significant decrease in BMD of the PT, DF, and fourth LVB. The ORX-induced decrease in BMD of the PT was more pronounced when combined with NX. Etidronate treatment for NX, ORX, and ORX + NX rats significantly decreased levels of urinary Dpd and serum Oc, resulting in complete prevention of loss of BMD and/or bone mechanical strength. The present study demonstrates the efficacy of etidronate treatment for prevention of bone loss caused by testosterone deficiency and immobilization in adult male rats.

Original languageEnglish
Pages (from-to)360-367
Number of pages8
JournalBone
Volume30
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Etidronic Acid
Bone Density
Osteocalcin
Bone and Bones
Serum
Orchiectomy
Tokyo
Photon Absorptiometry
Therapeutics
Tibia
Immobilization
Femur
Testosterone
Wistar Rats
Japan
Enzyme-Linked Immunosorbent Assay
Control Groups
deoxypyridinoline

Keywords

  • Bone mineral density (BMD)
  • Bone resorption
  • Etidronate
  • Orchidectomy (ORX)
  • Osteoporosis
  • Sciatic neurectomy

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Iwamoto, J., Takeda, T., Katsumata, T., Tanaka, T., Ichimura, S., & Toyama, Y. (2002). Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats. Bone, 30(2), 360-367. https://doi.org/10.1016/S8756-3282(01)00687-1

Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats. / Iwamoto, J.; Takeda, T.; Katsumata, T.; Tanaka, T.; Ichimura, S.; Toyama, Y.

In: Bone, Vol. 30, No. 2, 2002, p. 360-367.

Research output: Contribution to journalArticle

Iwamoto, J, Takeda, T, Katsumata, T, Tanaka, T, Ichimura, S & Toyama, Y 2002, 'Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats', Bone, vol. 30, no. 2, pp. 360-367. https://doi.org/10.1016/S8756-3282(01)00687-1
Iwamoto J, Takeda T, Katsumata T, Tanaka T, Ichimura S, Toyama Y. Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats. Bone. 2002;30(2):360-367. https://doi.org/10.1016/S8756-3282(01)00687-1
Iwamoto, J. ; Takeda, T. ; Katsumata, T. ; Tanaka, T. ; Ichimura, S. ; Toyama, Y. / Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats. In: Bone. 2002 ; Vol. 30, No. 2. pp. 360-367.
@article{45c2580a7de245cc834cff83c931046f,
title = "Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats",
abstract = "The purpose of the present study was to determine whether etidronate treatment could prevent bone loss caused by orchidectomy (ORX) and unilateral sciatic neurectomy (NX) in adult male rats. Seventy-four male Wistar rats, aged 10 months, were randomly divided into eight groups: baseline controls (n = 10); age-matched sham-operated controls (AMC; n = 9); ORX (n = 9); NX (n = 10); ORX + NX (n = 9); ORX + etidronate treatment (ORX + E; n = 7); NX + E (n = 10); and ORX + NX + E (n = 10). Etidronate treatment (10 mg/kg per day subcutaneously) was initiated 2 weeks after surgery and was continued for 2 weeks. Four weeks after surgery, bone mineral density (BMD) of the proximal and middle tibia (PT and MT, respectively), distal and middle femur (DF and MF, respectively), and fourth lumbar vertebral body (LVB) was measured by dual-energy X-ray absorptiometry (Model DCS-600, Aloka, Tokyo, Japan). The mechanical properties of the MF and third LVB were measured by three-point bending and compression tests, respectively. Levels of urinary deoxypyridinoline (Dpd) and serum osteocalcin (Oc) were also measured by enzyme-linked immunosorbent assay. Four weeks of aging had no significant effects on BMD, bone mechanical properties, or bone markers. ORX significantly increased the levels of urinary Dpd and serum Oc, which resulted in significant decreases in BMD of the PT, MT, DF, MF, and fourth LVB, as well as the mechanical strength (maximum load) of the MF and third LVB. NX significantly increased levels of urinary Dpd and decreased levels of serum Oc, resulting in a significant decrease in BMD of the PT, DF, and fourth LVB. The ORX-induced decrease in BMD of the PT was more pronounced when combined with NX. Etidronate treatment for NX, ORX, and ORX + NX rats significantly decreased levels of urinary Dpd and serum Oc, resulting in complete prevention of loss of BMD and/or bone mechanical strength. The present study demonstrates the efficacy of etidronate treatment for prevention of bone loss caused by testosterone deficiency and immobilization in adult male rats.",
keywords = "Bone mineral density (BMD), Bone resorption, Etidronate, Orchidectomy (ORX), Osteoporosis, Sciatic neurectomy",
author = "J. Iwamoto and T. Takeda and T. Katsumata and T. Tanaka and S. Ichimura and Y. Toyama",
year = "2002",
doi = "10.1016/S8756-3282(01)00687-1",
language = "English",
volume = "30",
pages = "360--367",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats

AU - Iwamoto, J.

AU - Takeda, T.

AU - Katsumata, T.

AU - Tanaka, T.

AU - Ichimura, S.

AU - Toyama, Y.

PY - 2002

Y1 - 2002

N2 - The purpose of the present study was to determine whether etidronate treatment could prevent bone loss caused by orchidectomy (ORX) and unilateral sciatic neurectomy (NX) in adult male rats. Seventy-four male Wistar rats, aged 10 months, were randomly divided into eight groups: baseline controls (n = 10); age-matched sham-operated controls (AMC; n = 9); ORX (n = 9); NX (n = 10); ORX + NX (n = 9); ORX + etidronate treatment (ORX + E; n = 7); NX + E (n = 10); and ORX + NX + E (n = 10). Etidronate treatment (10 mg/kg per day subcutaneously) was initiated 2 weeks after surgery and was continued for 2 weeks. Four weeks after surgery, bone mineral density (BMD) of the proximal and middle tibia (PT and MT, respectively), distal and middle femur (DF and MF, respectively), and fourth lumbar vertebral body (LVB) was measured by dual-energy X-ray absorptiometry (Model DCS-600, Aloka, Tokyo, Japan). The mechanical properties of the MF and third LVB were measured by three-point bending and compression tests, respectively. Levels of urinary deoxypyridinoline (Dpd) and serum osteocalcin (Oc) were also measured by enzyme-linked immunosorbent assay. Four weeks of aging had no significant effects on BMD, bone mechanical properties, or bone markers. ORX significantly increased the levels of urinary Dpd and serum Oc, which resulted in significant decreases in BMD of the PT, MT, DF, MF, and fourth LVB, as well as the mechanical strength (maximum load) of the MF and third LVB. NX significantly increased levels of urinary Dpd and decreased levels of serum Oc, resulting in a significant decrease in BMD of the PT, DF, and fourth LVB. The ORX-induced decrease in BMD of the PT was more pronounced when combined with NX. Etidronate treatment for NX, ORX, and ORX + NX rats significantly decreased levels of urinary Dpd and serum Oc, resulting in complete prevention of loss of BMD and/or bone mechanical strength. The present study demonstrates the efficacy of etidronate treatment for prevention of bone loss caused by testosterone deficiency and immobilization in adult male rats.

AB - The purpose of the present study was to determine whether etidronate treatment could prevent bone loss caused by orchidectomy (ORX) and unilateral sciatic neurectomy (NX) in adult male rats. Seventy-four male Wistar rats, aged 10 months, were randomly divided into eight groups: baseline controls (n = 10); age-matched sham-operated controls (AMC; n = 9); ORX (n = 9); NX (n = 10); ORX + NX (n = 9); ORX + etidronate treatment (ORX + E; n = 7); NX + E (n = 10); and ORX + NX + E (n = 10). Etidronate treatment (10 mg/kg per day subcutaneously) was initiated 2 weeks after surgery and was continued for 2 weeks. Four weeks after surgery, bone mineral density (BMD) of the proximal and middle tibia (PT and MT, respectively), distal and middle femur (DF and MF, respectively), and fourth lumbar vertebral body (LVB) was measured by dual-energy X-ray absorptiometry (Model DCS-600, Aloka, Tokyo, Japan). The mechanical properties of the MF and third LVB were measured by three-point bending and compression tests, respectively. Levels of urinary deoxypyridinoline (Dpd) and serum osteocalcin (Oc) were also measured by enzyme-linked immunosorbent assay. Four weeks of aging had no significant effects on BMD, bone mechanical properties, or bone markers. ORX significantly increased the levels of urinary Dpd and serum Oc, which resulted in significant decreases in BMD of the PT, MT, DF, MF, and fourth LVB, as well as the mechanical strength (maximum load) of the MF and third LVB. NX significantly increased levels of urinary Dpd and decreased levels of serum Oc, resulting in a significant decrease in BMD of the PT, DF, and fourth LVB. The ORX-induced decrease in BMD of the PT was more pronounced when combined with NX. Etidronate treatment for NX, ORX, and ORX + NX rats significantly decreased levels of urinary Dpd and serum Oc, resulting in complete prevention of loss of BMD and/or bone mechanical strength. The present study demonstrates the efficacy of etidronate treatment for prevention of bone loss caused by testosterone deficiency and immobilization in adult male rats.

KW - Bone mineral density (BMD)

KW - Bone resorption

KW - Etidronate

KW - Orchidectomy (ORX)

KW - Osteoporosis

KW - Sciatic neurectomy

UR - http://www.scopus.com/inward/record.url?scp=0036168743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036168743&partnerID=8YFLogxK

U2 - 10.1016/S8756-3282(01)00687-1

DO - 10.1016/S8756-3282(01)00687-1

M3 - Article

VL - 30

SP - 360

EP - 367

JO - Bone

JF - Bone

SN - 8756-3282

IS - 2

ER -